155272-15-4

Usage

Uses

Used in Pharmaceutical Industry:
(8E)-8-[(2Z)-2-(2,3-dimethyl-4-oxocyclohexa-2,5-dien-1-ylidene)ethylidene]-1,3-diethyl-7-methyl-3,7,8,9-tetrahydro-1H-purine-2,6-dione is used as a potential pharmaceutical agent for its unique structure and properties, which may contribute to the development of new drugs targeting various diseases.
Used in Research and Development:
In the field of chemical research and development, (8E)-8-[(2Z)-2-(2,3-dimethyl-4-oxocyclohexa-2,5-dien-1-ylidene)ethylidene]-1,3-diethyl-7-methyl-3,7,8,9-tetrahydro-1H-purine-2,6-dione serves as a subject for studying the effects of its complex structure on its potential interactions with biological systems, possibly leading to the discovery of new therapeutic approaches or understanding of biological processes.
Used in Chemical Synthesis:
(8E)-8-[(2Z)-2-(2,3-dimethyl-4-oxocyclohexa-2,5-dien-1-ylidene)ethylidene]-1,3-diethyl-7-methyl-3,7,8,9-tetrahydro-1H-purine-2,6-dione may also be utilized in chemical synthesis processes, where its unique structure could be employed to create new molecules with specific properties for various applications, including but not limited to the pharmaceutical, agrochemical, or materials science industries.

Relevant academic research and scientific papers

Antidepressants

The present invention relates to an antidepressant containing as an active ingredient a xanthine derivative or a pharmaceutically acceptable salt thereof, the xanthine derivative being represented by Formula (I) : STR1 in which R1, R2, and R3 represent independently hydrogen, lower alkyl, lower alkenyl; R4 represents cycloalkyl, --(CH2)n --R5 (in which R5 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group; and n is an integer of 0 to 4), or STR2 (in which Y1 and Y2 represent independently hydrogen, halogen or lower alkyl; and Z represents substituted or unsubstituted aryl, STR3 (in which R6 represents hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro, or amino; and m represents an integer of 1 to 3), or a substituted or unsubstituted heterocyclic group); and X1 and X2 represent independently O or S.

Therapeutic agent for Parkinson's disease

Agents for the treatment of Parkinson''s disease contain, as an active ingredient, a xanthine derivative or a pharmaceutically acceptable salt thereof. The xanthine derivative is represented by the formula: STR1 in which R 1, R 2 are R 3 are independently hydrogen, lower alkyl, lower alkenyl, or lower alkynyl; and R 4 represents cycloalkyl, --(CH 2) n --R 5 (in which R 5 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group; and n is an integer of 0 to 4), or STR2 in which Y 1 and Y 2 represent independently hydrogen, halogen, or lower alkyl; and Z represents substituted or unsubstituted aryl, STR3 in which R 6 represents hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro, or amino; and m represents an integer of 1 to 4, or a substituted or unsubstituted heterocyclic group; and X 1 and X 2 represent independently O or S.